Assignee
CADILA PHARMACEUTICALS LTD
IN·8 granted patents·7 pending applications·45 citations·filing 1998–2019
Top patents by PatentIndex Score
15 records- 0181US10335472B2Therapeutic cancer vaccineCADILA PHARMACEUTICALS LTD·Filed 2017·Granted Jul 2, 2019·2 cites·7 claims
- 0277US8048434B2Vaccine adjuvantsCADILA PHARMACEUTICALS LTD·Filed 2006·Granted Nov 1, 2011·3 cites·22 claims
- 0373US7972609B2Method of treating cancerCADILA PHARMACEUTICALS LTD·Filed 2002·Granted Jul 5, 2011·7 cites·29 claims
- 0467US11219674B2Therapeutic cancer vaccineCADILA PHARMACEUTICALS LTD·Filed 2019·Granted Jan 11, 2022·0 cites·6 claims
- 0563US9708258B2Indole 3-carbinol derivativesCADILA PHARMACEUTICALS LTD·Filed 2014·Granted Jul 18, 2017·2 cites·11 claims
- 0662US6306391B1Preparation of an oral pharmaceutical formulation containing an anti-infective agent and a microorganismCADILA PHARMACEUTICALS LTD·Filed 1998·Granted Oct 23, 2001·31 cites·16 claims
- 0755US2011020440A1Stable solutions of sparingly soluble activesCADILA PHARMACEUTICALS LTD·Filed 2008·Application pending·0 cites
- 0849US2010113802A1Process for preparing amorphous atorvastatin hemi calcium salt and its itermediateCADILA PHARMACEUTICALS LTD·Filed 2007·Application pending·0 cites
- 0947US9415078B2Method of treating desmocollin-3 expressing cancer with Mycobacterium wCADILA PHARMACEUTICALS LTD·Filed 2015·Granted Aug 16, 2016·0 cites·7 claims
- 1047US2010209394A1Mitogen activated protein kinase modulatorCADILA PHARMACEUTICALS LTD·Filed 2008·Application pending·0 cites
- 1145US10882819B2Synthesis of novel intermediate(s) for preparing rivastigmineCADILA PHARMACEUTICALS LTD·Filed 2019·Granted Jan 5, 2021·0 cites·8 claims
- 1244US2014045771A1Novel dipeptidyl peptidase iv (dp-iv) compoundsCADILA PHARMACEUTICALS LTD·Filed 2013·Application pending·0 cites
- 1342US2002025309A1Stable oral pharmaceutical formulation containing an anti-infective agent and a microorganismCADILA PHARMACEUTICALS LTD·Filed 2001·Application pending·0 cites
- 1440US2009177008A1Novel process for synthesis of itopride and its novel intermediate n-(4-hydroxybenzyl)- 3,4-dimethoxybenzamideCADILA PHARMACEUTICALS LTD·Filed 2006·Application pending·0 cites
- 1538US2018042850A1Pharmaceutical Composition of Killed Cells with Substantially Retained ImmunogenicityCADILA PHARMACEUTICALS LTD·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →